U.S. Senator Lindsey Graham has expressed support for President Donald Trump’s recent executive order aimed at reducing prescription drug prices in the United States. The order seeks to address the disparity in drug costs between the U.S. and other developed nations by ensuring that American consumers are not charged more than their counterparts abroad.
Graham stated, “I am very pleased that President Trump is standing up for American consumers when it comes to purchasing prescription drugs.” He highlighted the current system’s imbalance, where Americans pay significantly more due to other countries imposing price limits on drugs, leading pharmaceutical companies to recoup research and development costs from U.S. consumers.
The executive order introduces a “Most-Favored-Nation” clause, which requires pharmaceutical companies to offer Americans prices comparable to those in other developed countries. This measure aims to lower drug prices domestically while encouraging international partners to contribute more towards research and development expenses.
Graham noted that U.S.-based companies are responsible for over half of global pharmaceutical research and development efforts. He emphasized the need for other developed nations to share these costs rather than solely benefiting from American advancements.
